Can patients with hepatic insufficiency use Linagliptin tablets?

Generally, patients with hepatic impairment can use Linagliptin tablets. The detailed analysis is as follows:

Linagliptin tablets are primarily excreted via bile and the intestinal tract, making it the only dipeptidyl peptidase-4 (DPP-4) inhibitor predominantly eliminated through non-renal pathways. This indicates that the drug is mainly eliminated through the gastrointestinal system rather than being significantly metabolized by the liver. Therefore, hepatic impairment has minimal impact on the excretion of linagliptin. Although linagliptin undergoes hepatic metabolism, its primary metabolite, CD1790, is inactive. This means that even if liver function is impaired, there will be no accumulation of active metabolites, thereby reducing the burden and potential damage to the liver.

Linagliptin stimulates insulin release and inhibits glucagon secretion in a glucose-dependent manner. Therefore, whether used as monotherapy or in combination with other medications, it does not increase the risk of hypoglycemia. This is an important safety factor for patients with hepatic impairment.

Although linagliptin is relatively safe for patients with hepatic impairment, patients should still take the medication under the guidance of a physician and regularly monitor liver function and blood glucose levels to ensure safe and effective medication use.